Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) Expected to Announce Quarterly Sales of $4.25 Million

Brokerages predict that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will report $4.25 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Adaptimmune Therapeutics’ earnings. The highest sales estimate is $7.00 million and the lowest is $1.50 million. Adaptimmune Therapeutics reported sales of $40.79 million during the same quarter last year, which indicates a negative year-over-year growth rate of 89.6%. The firm is scheduled to announce its next earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year sales of $9.40 million for the current financial year, with estimates ranging from $200,000.00 to $20.00 million. For the next year, analysts forecast that the company will report sales of $17.75 million, with estimates ranging from $1.00 million to $36.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.07). The company had revenue of $0.16 million during the quarter, compared to analyst estimates of $4.25 million. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 42.78%.

ADAP has been the subject of several analyst reports. BidaskClub cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, July 26th. Guggenheim cut Adaptimmune Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. Leerink Swann cut Adaptimmune Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.15 price objective for the company. in a report on Tuesday, May 7th. Svb Leerink reissued a “market perform” rating and issued a $5.00 price objective (down previously from $12.00) on shares of Adaptimmune Therapeutics in a report on Tuesday, May 7th. Finally, Citigroup reissued a “buy” rating and issued a $8.00 price objective on shares of Adaptimmune Therapeutics in a report on Thursday, May 30th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $6.59.

Shares of ADAP stock traded up $0.12 on Wednesday, hitting $1.75. The company had a trading volume of 186,296 shares, compared to its average volume of 438,643. The firm has a market cap of $170.65 million, a P/E ratio of -1.82 and a beta of 1.62. The company has a 50-day moving average price of $2.90 and a 200-day moving average price of $3.88. The company has a quick ratio of 6.19, a current ratio of 6.19 and a debt-to-equity ratio of 0.13. Adaptimmune Therapeutics has a twelve month low of $1.44 and a twelve month high of $14.54.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADAP. Man Group plc raised its holdings in Adaptimmune Therapeutics by 37.4% in the 2nd quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock worth $7,394,000 after purchasing an additional 500,595 shares during the period. Rathbone Brothers plc raised its holdings in Adaptimmune Therapeutics by 146.6% in the 2nd quarter. Rathbone Brothers plc now owns 704,472 shares of the biotechnology company’s stock worth $2,832,000 after purchasing an additional 418,750 shares during the period. Baillie Gifford & Co. raised its holdings in Adaptimmune Therapeutics by 7.9% in the 2nd quarter. Baillie Gifford & Co. now owns 4,143,840 shares of the biotechnology company’s stock worth $16,658,000 after purchasing an additional 304,650 shares during the period. Deutsche Bank AG raised its holdings in Adaptimmune Therapeutics by 1,681,328.6% in the 4th quarter. Deutsche Bank AG now owns 117,700 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 117,693 shares during the period. Finally, BlackRock Inc. raised its holdings in Adaptimmune Therapeutics by 10.4% in the 4th quarter. BlackRock Inc. now owns 856,415 shares of the biotechnology company’s stock worth $4,924,000 after purchasing an additional 81,010 shares during the period. 66.24% of the stock is owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Recommended Story: What are the risks of holding treasury bonds?

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.